- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$740.92 MnMarket Estimate, 2026
$791.46 MnMarket Forecast, 2034
$1,341.68 MnCAGR, 2026–2034
6.82%Executive Summary: North America Biopsy Devices Market
- Market Scope: Regional analysis of North America's biopsy devices sector, detailing product frameworks, procedural types, clinical applications, end-user settings, and country-level profiles across the forecast period 2026-2034.
- Market Valuation: Valued at USD 740.92 million in 2025, reaching USD 791.46 million in 2026, and projected to expand to USD 1,341.68 million by 2034, growing at a robust CAGR of 6.82% from 2026 to 2034.
- Primary Growth Drivers: Rising prevalence of cancer cases across North America, increasing preference for minimally invasive surgeries, and rapid technological advancements in automated biopsy instruments and needles.
Key Market Segment Metrics
| Category | Leading Segment (Base Position) | Fastest-Growing / High-Growth Segment |
|---|---|---|
| By Product | Consumables (dominated the market share, driven by high procedural volumes of single-use needles, reagents, and collection kits) | Instruments (projected for strong growth, fueled by the adoption of automated and semi-automated biopsy systems) |
| By Type | Needle Biopsy (held the major share, supported by core needle and vacuum-assisted precision tissue extraction) | Vacuum-Assisted Needle Biopsy (fastest-growing segment driven by high diagnostic accuracy and minimal trauma) |
| By Application | Medical Diagnosis (captured the largest share, anchored by oncology screening and chronic disease detection) | Scientific Research & Genetic Fingerprinting (growing rapidly due to molecular profiling and biopharma studies) |
| By End User | Pharmaceutical and Biology Industry / Hospitals & Diagnostics Centers (led market demand for clinical trials and routine pathology) | Contract Research Organizations (expanding via outsourced oncology trials and advanced biomarker evaluations) |
| By Country | United States (market leader backed by advanced medical infrastructure, top-tier manufacturing hubs, and high cancer incidence) | Canada (witnessing a healthy CAGR driven by increasing clinical trial centers, government awareness programs, and favorable reimbursement) |
Major Market Players & Industry Landscape
Market Structure: Highly competitive landscape characterized by major MedTech innovators focusing on precision engineering, automation, and reduced procedural error.
Key Companies: Medtronic, Leica Biosystems, Hologic Inc., Boston Scientific Corporation, Becton, Dickinson and Company, Cook Medical Inc., C.R. Bard Inc., Mauna Kea Technologies, Ethicon Endo-Surgery Inc., Veran Medical Technologies, Fujifilm Medical Systems, MDxHealth, Argon Medical Devices Inc., and Intact Medical Corp.
North America Biopsy Devices Market Size
The North America Biopsy Devices Market is projected to grow from USD 740.92 million in 2025 to USD 791.46 million in 2026 and reach USD 1,341.68 million by 2034, registering a CAGR of 6.82% during the forecast period from 2026 to 2034.
The growing number of cancer patients in North America primarily drive the North American biopsy devices market growth. The rising demand for biopsy devices to diagnose cancer cells is prompting the market demand. A biopsy is a procedure to remove a piece of tissue from the body. Some common types of biopsies are breast biopsy, prostate biopsy, liver biopsy, hat biopsy, skin biopsy, etc. Several laboratory tests have been done samples for the determination of the issue. In the healthcare sector, imaging tests such as CT and MRI are used for detecting masses and irregular tissue, but they cannot determine whether it is cancerous cells. As a result, healthcare providers prefer the biopsy procedure, which is done using biopsy devices to help with market demand. A biopsy is also used to detect infections, such as tuberculosis, and immune disorders, such as chronic pancreatic, ulcer, and endometriosis.
The rising preference for minimally invasive surgeries contributes to the biopsy devices market growth in North America. Due to fewer cuts and less blood flow, patients are adopting minimal invasion surgery. It also takes less operational time, fewer hospital stays, and less recovery time. In recent years, most of the geriatric population are adopting minimal invasion surgery to detect cancer through biopsy. Biopsy devices are also used in surgical procedures in the removal of tissue for the further detection.
The growing number of advancements in the manufacturing of biopsy devices and increasing R&D activities around biopsy devices supports the North American market growth. Manufacturers are focused on the development of various types of needles that are used during biopsy procedures. Needles play a major role in the removal of required tissue for the detection of cancer. They also focus on developing biopsy instruments and automation equipment, which reduce human errors during the surgical procedure. Increasing use of advanced technologies in manufacturing devices, increasing support of healthcare organizations, and increasing presence of key players will fuel the market growth in the coming years.
The high cost of the biopsy device primarily hinders the North American market growth. Lack of awareness about the procedures, high cost of the biopsy procedures, and lack of skilled professionals further impedes the market growth in North America.
MARKET SEGMENTATION
This research report on the North American Biopsy Devices Market has been segmented & sub-segmented into the following categories
North America Biopsy Devices Market - By Product
-
Instruments
-
Manual
- Automated
- Semi-automated
-
- Consumables
- Reagents
- Kits
North America Biopsy Devices Market - By Type
-
Needle Biopsy
-
core needle biopsy
- fine-needle biopsy
- vacuum-assisted biopsy
-
- Surgical Biopsy
- Incisional biopsy
- Excisional biopsy
North America Biopsy Devices Market - By Application
-
Scientific Research
-
Medical Diagnosis
- Agricultural Applications
- Genetic Fingerprinting
- Sex Determination
North America Biopsy Devices Market - By End User
-
Pharmaceutical and Biology Industry
-
Academic Research Institute
- Contract Research Organizations
- Forensic Labs
North America Biopsy Devices Market - By Country
-
The United States
-
Canada
- Rest of North America
North America held the largest share of the worldwide market in 2023 and is expected to continue the domination throughout the forecast period owing to the presence of advanced medical devices in the healthcare sector and the increasing healthcare expenditure by the population. The government has followed several measures to approve and launch the novel biopsy device to reduce errors during surgical procedures.
The U.S. led the market in North America in 2023 and is expected to continue the lead in the coming years due to the presence of manufacturing centers and the increasing presence of key players. Increasing numbers of specialized professionals, increasing the number of diagnostic centers and pathology centers, and increasing cancer hospitals are the other factor that raises the market demand. For instance, nearly 1.9 million new cancer cases have reported in the United States region in 2023.
Canada is estimated to witness a healthy CAGR in the coming years. Factors such as the increasing number of clinical trial centers and increasing reimbursement policies for surgeries drivee the Canadian market growth. Canada's government has conducted several awareness programs about the biopsy procedure, which helps detect cancer or noncancerous cell for early prevention of the diseases.
KEY MARKET PLAYERS
Companies playing a dominating role in the North American biopsy devices market are Medtronic, Leica Biosystems, Hologic Inc., Boston Scientific Corporation, Becton, Cook Medical Inc., C.R. Bard Inc., Mauna Kea Technologies, Ethicon EndoSurgery Inc., Veran Medical Technologies, Dickinson and Company, Fujifilm Medical Systems, MDxHealth, Argon Medical Devices Inc and Intact Medical Corp.